Alpelisib - Novartis Oncology
Alternative Names: Alpericive - Novartis Oncology; BYL-719; NVP-BYL-719; Piqray; VijoiceLatest Information Update: 03 Jun 2025
At a glance
- Originator Novartis
- Developer Columbia University; H. Lee Moffitt Cancer Center and Research Institute; Kura Oncology; Memorial Sloan-Kettering Cancer Center; Novartis; Novartis Oncology; Peter MacCallum Cancer Centre; University Health Network
- Class Amides; Antineoplastics; Fluorine compounds; Pyridines; Pyrrolidines; Small molecules; Thiazoles
- Mechanism of Action Phosphatidylinositol 3 kinase alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed HER2 negative breast cancer
- Registered Growth disorders
- Phase III Head and neck cancer; HER2 positive breast cancer; Triple negative breast cancer
- Phase II/III Lymphatic disorders
- Phase II Breast cancer
- Discontinued Gastric cancer; Gastrointestinal stromal tumours; Multiple myeloma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Rectal cancer; Solid tumours; Uveal melanoma
Most Recent Events
- 30 May 2025 Novartis Pharmaceuticals plans to initiate a phase II trial for Growth Disorder (In adolescents, In adults, In children, In the elderly) (PO) (NCT06997588)
- 28 Mar 2025 No recent reports of development identified for phase-I development in Growth-disorders(In volunteers) in United Kingdom (PO, Tablet)
- 02 Jan 2025 Chemical structure information added.